EX-99.1 2 dex991.htm PRESS RELEASE DATED AUGUST 9, 2004, OF THE REGISTRANT Press Release dated August 9, 2004, of the Registrant

EXHIBIT 99.1

 

NEWS RELEASE

 

CONTACT:  

Investor Relations

   

Irvine Sensors Corporation

   

714-444-8718

   

investorrelations@irvine-sensors.com

 

FOR IMMEDIATE RELEASE

 

IRVINE SENSORS RELEASES 3rd QUARTER RESULTS

 

COSTA MESA, CALIFORNIA — August 9, 2004 — Irvine Sensors Corporation (NASDAQ: IRSN, Boston Stock Exchange: ISC) today reported operating results for its third fiscal quarter and 39 weeks ended June 27, 2004.

 

Total revenues for the third quarter of fiscal 2004 were $3,542,600, up $1,145,900, or 48%, from $2,396,700 in the third quarter of fiscal 2003, largely reflecting an increase in the Company’s contract research and development revenue in the current fiscal year period. Total revenues for the 39-week period ended June 27, 2004 were $9,408,700, a decrease of $672,500, or 7%, from $10,081,200 in total revenues realized in last year’s 39-week period ended June 29, 2003. Net losses for both the 13-week and 39-week periods in the current fiscal year were reduced from net losses in the comparable fiscal 2003 periods. Net loss for the 13-week period ended June 27, 2004 was $720,000, down $940,000, or 57%, from the $1,660,000 net loss for the 13-week period ended June 29, 2003. The net loss through the first 39 weeks of the current fiscal year was $3,229,400, a $1,152,000, or 26%, decrease from the $4,381,400 net loss in the first 39 weeks of fiscal 2003.

 

Irvine Sensors Corporation, headquartered in Costa Mesa, California, is primarily engaged in the sale of stacked chip assemblies and research and development related to high density electronics, miniaturized sensors and cameras, optical interconnection technology, high speed routers, image processing and low-power analog and mixed-signal integrated circuits for diverse systems applications.

 

 

—00—


IRVINE SENSORS CORPORATION

CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

 

     13 Weeks Ended

    39 Weeks Ended

 
    

June 27,

2004


   

June 29,

2003


   

June 27,

2004


   

June 29,

2003


 

Revenues:

                                

Contract research and development revenue

   $ 3,257,000     $ 2,054,300     $ 8,027,000     $ 8,255,200  

Product sales

     281,300       341,500       1,336,100       1,789,000  

Other revenue

     4,300       900       45,600       37,000  
    


 


 


 


Total revenues

     3,542,600       2,396,700       9,408,700       10,081,200  
    


 


 


 


Costs and expenses:

                                

Cost of contract research and development revenue

     2,048,200       1,262,800       5,208,800       6,390,800  

Cost of product sales

     280,900       448,000       1,561,700       1,808,400  

General and administrative expense

     1,496,000       1,311,300       4,274,400       4,358,400  

Research and development expense

     397,200       783,000       1,494,500       1,522,200  
    


 


 


 


Total costs and expenses

     4,222,300       3,805,100       12,539,400       14,079,800  
    


 


 


 


Loss from operations

     (679,700 )     (1,408,400 )     (3,130,700 )     (3,998,600 )

Interest expense

     (30,700 )     (20,400 )     (75,700 )     (138,300 )

Loss on disposal of assets

     (9,600 )     (233,000 )     (16,400 )     (238,800 )

Interest and other income

     800       100       1,200       4,800  
    


 


 


 


Loss before minority interest and provision for income taxes

     (719,200 )     (1,661,700 )     (3,221,600 )     (4,370,900 )

Minority interest in loss of subsidiaries

     1,400       3,000       7,200       4,900  

Provision for income taxes

     (2,200 )     (1,300 )     (15,000 )     (15,400 )
    


 


 


 


Net loss

     (720,000 )     (1,660,000 )     (3,229,400 )     (4,381,400 )
    


 


 


 


Imputed dividend on Series E stock issued

     —         (92,800 )     —         (1,013,100 )
    


 


 


 


Net loss applicable to common stockholders

   $ (720,000 )   $ (1,752,800 )   $ (3,229,400 )   $ (5,394,500 )
    


 


 


 


Basic and diluted net loss per common share (Note 5)

   $ (0.05 )   $ (0.20 )   $ (0.21 )   $ (0.67 )
    


 


 


 


Weighted average number of shares outstanding

     15,945,800       8,827,900       15,085,300       8,104,000  
    


 


 


 



IRVINE SENSORS CORPORATION

CONSOLIDATED BALANCE SHEETS

 

    

June 27,

2004


    September 28,
2003


 
     (Unaudited)        

Assets

                

Current assets:

                

Cash and cash equivalents

   $ 3,271,800     $ 1,166,800  

Restricted cash

     35,200       54,200  

Accounts receivable, net of allowance for doubtful accounts of $10,000 and $57,700, respectively

     685,600       443,500  

Unbilled revenues on uncompleted contracts

     1,345,300       598,100  

Inventory, net

     1,178,800       932,100  

Other current assets

     69,900       48,500  
    


 


Total current assets

     6,586,600       3,243,200  

Equipment, furniture and fixtures, net

     4,499,900       4,417,600  

Patents and trademarks, net

     729,300       707,400  

Deposits

     87,600       87,400  
    


 


Total assets

   $ 11,903,400     $ 8,455,600  
    


 


Liabilities and Stockholders’ Equity

                

Current liabilities:

                

Accounts payable

   $ 1,401,300     $ 1,620,600  

Accrued expenses

     886,600       806,100  

Accrued loss on contracts

     40,600       358,500  

Advance billings on uncompleted contracts

     40,700       437,000  

Deferred revenue

     28,100       251,700  

Capital lease obligations – current portion

     93,700       30,700  
    


 


Total current liabilities

     2,491,000       3,504,600  

Capital lease obligations, less current portion

     165,200       34,700  

Minority interest in consolidated subsidiaries

     424,300       431,500  
    


 


Total liabilities

     3,080,500       3,970,800  
    


 


Commitments and contingencies

     —         —    

Stockholders’ Equity:

                

Preferred stock, $0.01 par value, 500,000 shares authorized; Series E convertible preferred stock, 0 and 2,083 shares outstanding

     —         —    

Common stock, $0.01 par value, 80,000,000 shares authorized; 17,644,500 and 12,947,700 shares issued and outstanding

     176,400       129,500  

Common stock warrants; 1,508,100 and 2,065,600 warrants outstanding

     —         —    

Unamortized employee stock bonus plan contribution

     (109,400 )     —    

Common stock held by Rabbi Trust

     (250,000 )     (250,000 )

Deferred compensation liability

     250,000       250,000  

Paid-in capital

     117,945,500       110,315,500  

Accumulated deficit

     (109,189,600 )     (105,960,200 )
    


 


Total stockholders’ equity

     8,822,900       4,484,800  
    


 


     $ 11,903,400     $ 8,455,600